ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Erasca, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$13.62+0.23 (+1.72%)
Close on Oct 19, 2026
- Market cap
- $4.24B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 159.4% | -33.3% | |
| Return on assets | – | – | -27.7% | |
| Current ratio | – | 8.77 | 10.04 | |
| Diluted shares | – | 21M | 284M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Erasca generated $488.95M from operations and spent $27.72M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$488.95M
Used
$27.72M
Capital expenditure$27.72M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$124.55M
- Cash generatingOperating cash flow above zero-$95.46M
- Return on assets improvedROA up on the prior year-40.9% → -24.8%
- Earnings backed by cashOperating cash flow above net income-$95.46M vs -$124.55M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.84 → 10.04
- No dilutionShare count did not rise234M → 284M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –